bims-tuinly Biomed News
on Tumor-infiltrating lymphocytes therapy
Issue of 2026–09–27
23 papers selected by
Pierpaolo Ginefra, Ludwig Institute for Cancer Research



  1. Curr Oncol. 2026 Aug 24. pii: 498. [Epub ahead of print]33(9):
      Tumor-infiltrating lymphocyte (TIL) therapy is the first adoptive cellular therapy approved to treat solid tumors and has demonstrated durable responses in advanced melanoma. However, its clinical implementation is limited by the need for tumor harvesting, manufacturing delays, and lymphodepleting conditioning. These logistic challenges are also opportunities for physicians and scientists to consider combining TIL therapy with radiation therapy (RT), a modality with well-established roles in cancer care. RT exerts both immunostimulatory and immunosuppressive effects, influencing antigen presentation and T-cell trafficking while also contributing to lymphocyte depletion in a dose- and context-dependent manner. These properties provide a strong biologic rationale for integration with TIL therapy but also introduce important uncertainties. Preclinical studies suggest RT can enhance TIL expansion and function, while early clinical experience supports the feasibility of RT delivery before and after TIL therapy in selected scenarios. However, prospective clinical data remain limited, and key questions regarding optimal timing, dose, and target selection are unresolved. In this review, we propose a workflow-based framework for combining RT with TIL therapy across pre-harvest, bridging, peri-infusion, and post-infusion settings. RT is a promising partner to TIL therapy, but prospective studies will ultimately be needed to define how best to integrate RT in order to translate biologic synergy into consistent clinical benefit.
    Keywords:  adoptive cell therapy; immunotherapy; low dose radiation therapy; lymphodepletion; melanoma; radiation therapy; tumor microenvironment; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3390/curroncol33090498
  2. Front Immunol. 2026 ;17 1879640
       Background: Stromal tumor-infiltrating lymphocytes (TILs) are established biomarkers in triple-negative breast cancer (TNBC), but conventional density-based assessment does not capture their spatial relationship to tumor nests. We evaluated whether an H&E-derived spatial architecture index (SAI) provides predictive information beyond stromal TIL density for pathologic complete response (pCR) after neoadjuvant therapy.
    Methods: This single-center retrospective cohort included 236 patients with TNBC who had evaluable pretreatment core biopsy slides and definitive surgical response assessment. The primary SAI was the equally weighted mean of standardized close interaction ratio and lymphocyte cluster index, together with reverse-coded standardized lymphocyte-tumor distance and edge enrichment. The primary multivariable analysis included 231 patients with complete clinicopathologic data. Robustness was evaluated using bootstrap optimism correction, alternative SAI constructions, treatment-regimen and propensity-score analyses, repeated nested cross-validation, and a 60-case reproducibility assessment. During internal validation, preprocessing and SAI construction were repeated within each training fold.
    Results: Of 236 patients, 122 (51.7%) achieved pCR. In the main multivariable model, the SAI remained associated with pCR (OR 2.79 per 1 SD, 95% CI 1.79-4.35; P < 0.001), whereas stromal TIL density was not independently significant (OR 0.88 per 10% increase, 95% CI 0.74-1.04; P = 0.123). Bootstrap optimism-corrected AUROCs were 0.698 for the clinical model, 0.705 after the addition of stromal TIL density, 0.764 after the addition of the SAI, and 0.765 after the addition of both. Across six internally validated algorithms using the full feature set, mean AUROCs ranged from 0.730 to 0.752, with only modest between-algorithm differences. The SAI showed excellent interobserver reproducibility (ICC 0.93, 95% CI 0.89-0.95). Its association with pCR persisted in the chemotherapy-only subgroup (OR 2.48, 95% CI 1.52-4.05; P < 0.001), whereas the interaction with pembrolizumab-containing treatment was not significant (P = 0.222).
    Conclusion: In this exploratory single-center retrospective cohort, the H&E-derived SAI provided internally validated predictive information beyond stromal TIL density for pCR. External multicenter validation, assessment of intersite technical reproducibility, and prospective calibration are required before clinical implementation.
    Keywords:  digital pathology; machine learning; neoadjuvant therapy; pathologic complete response; spatial architecture; triple-negative breast cancer; tumor immune microenvironment; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3389/fimmu.2026.1879640
  3. Int J Surg Pathol. 2026 Sep 19. 10668969261470846
      ObjectiveGallbladder cancer (GBC) is a rare, aggressive malignancy with poor survival outcomes. The tumor microenvironment (TME), which includes stromal content, immune infiltration, and tumor budding, influences tumor progression and prognosis. ANXA1 is a multifunctional protein that mediates crosstalk within the TME to regulate cancer cell behavior and stromal dynamics; however, its prognostic role in GBC remains unclear.Patients and MethodsWe retrospectively analyzed 131 patients who underwent surgery for primary GBC. Tumor-stroma ratio (TSR), local immune responses [Klintrup-Mäkinen (KM) grade, stromal tumor-infiltrating lymphocytes (TILs), and Crohn-like lymphoid reaction (CLR)], tumor budding, and ANXA1 expression were evaluated using hematoxylin and eosin-stained slides and immunohistochemistry. Associations with clinicopathological features, disease-specific survival (DSS), and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and Cox regression models.ResultsHigh-grade tumor budding was observed in 23% of tumors, and a stroma-high phenotype was identified in 29%. ANXA1 expression was positive in 80.9% of the tumors. Stroma high status and high-grade tumor budding were identified as independent predictors of poor DSS, whereas high-grade tumor budding independently predicted poor PFS. Low KM grade, stromal TILs, CLR, and ANXA1 expression were not independently associated with survival.ConclusionsHigh-grade tumor budding and stroma-rich phenotypes were independent adverse prognostic factors for GBC, whereas stromal TILs were associated with favorable outcomes. Although ANXA1 is expressed in GBC and linked to aggressive features, it does not independently predict survival. A comprehensive assessment of TME components may improve prognostic stratification and guide personalized management strategies for GBC.
    Keywords:  annexin A1; gallbladder cancer; tumor budding; tumor microenvironment; tumor-infiltrating lymphocytes; tumor–stroma ratio
    DOI:  https://doi.org/10.1177/10668969261470846
  4. Front Immunol. 2026 ;17 1909913
      Osteosarcoma(OS) exhibits poor and heterogeneous responses to immune checkpoint inhibitors(ICIs), largely due to its highly tumor immunosuppressive microenvironment(TIME). This review explores how nutritional biomarkers regulate the OS tumor microenvironment(TME) and serve as predictors of ICIs efficacy. Key biomarkers, including prognostic nutritional index(PNI), vitamin D and IDO modulate tumor-infiltrating lymphocytes (TILs), CD8+ T-cell function, macrophage polarization, and cytokine-metabolite crosstalk through mechanisms such as nutrient depletion, lactate acidification, and inflammatory signaling. These biomarkers not only reflect host nutritional and inflammatory status but also actively shape an TIME that contributes to ICIs resistance. Targeted nutritional interventions and combinations with IDO show potential to reprogram the TME and enhance antitumor immunity. This review highlights the value of nutritional biomarkers for patient stratification, prognostic assessment, and the development of personalized nutrition-immunotherapy strategies, providing a foundation for overcoming treatment resistance in OS.
    Keywords:  ICIs - immune check point inhibitors; TME; biomarker; nutrition; osteosarcoma
    DOI:  https://doi.org/10.3389/fimmu.2026.1909913
  5. Curr Issues Mol Biol. 2026 Sep 03. pii: 899. [Epub ahead of print]48(9):
       BACKGROUND/OBJECTIVES: Neoadjuvant therapy (NAT) may remodel the breast-cancer microenvironment. We evaluated paired changes in programmed death-ligand 1 (PD-L1), vascular endothelial growth factor (VEGF), and tumor-infiltrating lymphocytes (TILs) before and after NAT, and associations with the residual cancer burden (RCB) and survival.
    METHODS: This retrospective study included 102 patients with residual invasive breast cancer after NAT: 34 with luminal B-like/HER2-negative, 34 with luminal B-like/HER2-positive, and 34 with triple-negative breast cancer (TNBC). PD-L1 was assessed using the 22C3 combined positive score, VEGF by the cytoplasmic staining intensity, and stromal TILs according to international recommendations.
    RESULTS: The median tumor size decreased from 2.5 to 1.7 cm (p < 0.001), the PD-L1 CPS (combined positive score) from 6 to 5 (p = 0.039), and the TILs from 15% to 10% (p < 0.001), whereas VEGF shifted toward stronger staining (p = 0.03). In TNBC, the PD-L1 CPS decreased from 10 to 5 (p = 0.003) and the TILs from 20% to 8% (p < 0.001). Biomarkers were not associated with the RCB in the overall cohort. The initial tumor size predicted RCB II/III (OR: 2.60, p = 0.038). The overall survival differed by subtype (p < 0.001).
    CONCLUSIONS: NAT has induced subtype-dependent immune and angiogenic changes, supporting biomarker reassessment in residual disease.
    Keywords:  PD-L1; VEGF; breast cancer; neoadjuvant therapy; residual cancer burden; triple-negative breast cancer; tumor microenvironment; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3390/cimb48090899
  6. Med Image Anal. 2026 Sep 17. pii: S1361-8415(26)00403-2. [Epub ahead of print]115 104334
      Patients with advanced melanoma are treated with immune checkpoint inhibitors (ICIs), yet <50% of patients achieve a durable response while all patients are exposed to the risk of severe side effects. Tumor-infiltrating lymphocytes (TILs) in pathology images are associated with ICI outcomes, but manual assessment is subjective. In addition, the predictive value of other immune cell subsets, including plasma cells, neutrophils, histiocytes, and melanophages, remains unclear. We organized the Panoptic segmentation of nUclei and tissue in advanced MelanomA (PUMA) challenge to evaluate whether the spatial localization of TILs and other immune cell subsets on melanoma H&E slides collected before start of treatment was associated with treatment outcomes. Algorithm performance was evaluated on a hidden test set, after which top-ranked algorithms were applied to pre-treatment metastatic whole-slide images from a large, multicenter cohort of patients with advanced melanoma treated with first-line ICIs (n = 1102). Automatically quantified tissue features and immune cell subsets were then associated with clinical outcomes. Top-performing algorithms improved detection of immune cell subsets through pathology foundation model features, multi-stage tissue-context learning, and class-specific architectures, although accuracy for rare classes remained limited. Across challenge participants, TIL density showed the most consistent association with treatment response and survival. Associations for stromal TILs were weaker, while plasma cells, histiocytes, melanophages, neutrophils, necrosis and blood vessels did not show independent associations with outcomes. Overall, the PUMA challenge advanced immune cell detection in melanoma histopathology and showed that intratumoral lymphocytes are most consistently associated with treatment response and survival.
    Keywords:  Computational pathology; Grand challenge; Immune checkpoint inhibition; Melanoma
    DOI:  https://doi.org/10.1016/j.media.2026.104334
  7. JCO Precis Oncol. 2026 Sep;10(9): e2600278
       PURPOSE: Preoperative chemoradiotherapy (CRT) can reshape the composition of the tumor immune microenvironment (TIME) in locally advanced rectal cancer (LARC), augmenting T-cell density and activation. As TIME may provide predictive insights, we analyzed the association of immune cell distribution and remodeling after CRT with pathologic response and clinical outcomes in patients with LARC derived from the STAR-01 (fluorouracil-based CRT plus/minus oxaliplatin) trial.
    PATIENTS AND METHODS: Tumor-infiltrating lymphocytes (TILs) were assessed by standard stains and immunostains (CD3, CD20, CD4, CD8, FOXP3, PD-1, and CD68). Immune cell populations in pretreatment biopsies and post-treatment surgical specimens were compared and associated with complete pathological response (ypT0N0) and overall (OS) and event-free (EFS) survival.
    RESULTS: We retrieved 413 samples from 303 patients from the original cohort, including 110 paired pretreatment biopsies and post-treatment surgical tumor specimens. In pretreatment biopsies, CD20+ cell counts were associated with improved EFS (P = .051), independent of other prognostic factors. After therapy, intermediate-high TILs, CD3+ cells, low CD4+/CD8+ ratio, and CD68+ macrophage counts significantly increased, whereas FOXP3+ and CD20+ cells decreased. ypT0N0 was associated with low CD4+/CD8+ ratio (P < .001), reduced CD68+ (P = .001), and absence of eosinophils (P < .001) in post-treatment surgical specimens. In post-treatment specimens, low CD4+/CD8+ ratio and CD20+ cell counts were significantly associated with both improved EFS (CD4+/CD8+: P = .016; CD20+ cells: P = .002) and OS (CD4+/CD8+: P = .005; CD20+ cells: P = .014). This prognostic role was confirmed in a multivariable analysis for CD20+ cells.
    CONCLUSION: In LARC, CRT reshapes the type and amount of immune cell contents, and the effects on certain immune populations are associated with tumor regression and clinical outcome.
    DOI:  https://doi.org/10.1200/PO-26-00278
  8. J Immunother Cancer. 2026 Sep 21. pii: e015639. [Epub ahead of print]14(9):
       BACKGROUND: The immunosuppressive tumor microenvironment in hepatocellular carcinoma (HCC) limits the efficacy of current immunotherapies. The interplay between the emerging inhibitory receptor NKG2A and its activating counterpart NKG2C, both binding HLA-E, and its interaction with the PD-1-PD-L1 pathway in cancer remains unclear. This study aims to delineate the functional network formed by these pathways in shaping the immunosuppressive landscape of HCC.
    METHODS: We analyzed public databases and performed immunohistochemistry on HCC tissues to assess HLA-E expression and prognostic relevance. Tumor-infiltrating lymphocytes from patient samples were examined by flow cytometry to evaluate the functional impact of NKG2A, NKG2C, and PD-1 expression on T and NK cells. Single-cell RNA and T cell receptor (TCR) sequencing were employed to characterize immune subset heterogeneity. Functional assays and mouse models were used to evaluate the effects of NKG2A and PD-1 blockade.
    RESULTS: In the absence of CD8+ T cell infiltration, elevated HLA-E expression in HCC tissue correlated with poorer overall survival in non-immunotherapy-treated patients. Conversely, in the presence of CD8+ T cells, high HLA-E expression was linked to an inflammatory tumor microenvironment characterized by IFN-γ-producing T cells, and increased major histocompatibility complex I, which was associated with improved patient response to immunotherapy. Tumor-infiltrating CD8+ T and NK cells from HCC patients upregulated NKG2A, conferring tissue-resident memory and tumor-reactive characteristics while simultaneously impairing cytotoxic function. Single-cell RNA and TCR sequencing revealed differential expression patterns of NKG2A, NKG2C, and PD-1 in different T and NK cell subsets, with NKG2A+ PD-1+ T cells relevant to antigen-specific clonal expansion. Mechanistically, the inhibitory effect mediated by the NKG2A-HLA-E axis contributed more prominently than the stimulatory role of the NKG2C-HLA-E axis in suppressing antitumor immunity. Furthermore, the NKG2A-HLA-E axis acted cooperatively with the PD-1-PD-L1 axis to promote CD8+ T cell dysfunction. Combined blockade of NKG2A and PD-1 enhanced the cytotoxic activity of tumor-infiltrating CD8+ T and NK cells, resulting in potent tumor eradication in vitro and in vivo, outperforming single-agent treatments.
    CONCLUSIONS: Our findings identify the NKG2A-HLA-E axis as an important immunoregulatory pathway associated with immune suppression in HCC and provide a rationale for further evaluation of combined NKG2A and PD-1 blockade strategies.
    Keywords:  Hepatocellular Carcinoma ; Immune Checkpoint; Immune suppression; NK cell; T cell
    DOI:  https://doi.org/10.1136/jitc-2026-015639
  9. bioRxiv. 2026 Sep 18. pii: 2026.09.17.752425. [Epub ahead of print]
      Neoantigen immunogenicity prediction is fundamental to personalized cancer vaccines, tumor-infiltrating lymphocyte (TIL) therapy, and TCR-T cell engineering. Existing computational predictors rely primarily on in-vitro correlates of peptide presentation or models trained against assay-based reactivity, and they are typically validated within a single therapeutic setting. We reasoned that the most direct evidence of neoantigen immunogenicity is longitudinal in-vivo elimination: under immune checkpoint blockade (ICB), subclones bearing recognized neoantigens are selectively depleted over time. Here, we present the Neoantigen Elimination Model (NEMo), a two-compartment (CD8 and CD4) machine learning classifier trained on the in-vivo editing (IVE) of neoantigens across serially sequenced, ICB-treated tumors. By using mechanistically inspired NeoPrecis features designed to capture determinants of immunogenicity beyond MHC binding affinity, NEMo recovered assay-confirmed immunogenic neoantigens across four independent, unseen clinical settings -- pre-existing immunogenicity screening, personalized cancer vaccines, TIL therapy, and a radiotherapy +/- ICB ctDNA cohort -- and stratified progression-free survival more strongly than ELISPOT-confirmed reactivity. The editing signal further revealed an immune-evasion architecture in which oncogenic drivers and neoantigens restricted to lost or silenced HLA alleles are systematically spared from editing.
    DOI:  https://doi.org/10.64898/2026.09.17.752425
  10. Small. 2026 Sep 22. e75859
      Particle-based artificial antigen-presenting cells (aAPCs) are widely used for ex vivo T cell activation, but rigid, high-avidity stimulation can promote differentiation and exhaustion, reducing therapeutic efficacy. Because T cells sense mechanical forces through the T cell receptor, we engineered nanocapsule aAPCs with three stiffness regimes, spanning MPa to GPa Young's moduli, and two αCD3/αCD28 ligand densities to define how mechanical and biochemical cues shape primary human T cell responses. Across six formulations benchmarked against Dynabeads, stiffness and ligand density acted as orthogonal but synergistic design parameters. Expansion increased with both variables, and the stiff, high-density nanocapsules matched or exceeded Dynabead-mediated expansion by day 8. However, unlike Dynabeads, enhanced expansion did not coincide with strong exhaustion or terminal differentiation. Nanocapsules maintained CD8+ PD-1+ frequencies near baseline, mitigated Dynabead-associated CD4+ bias, and promoted CD8 enrichment, with CD8/CD4 ratios reaching approximately 2.7. They also produced transient, tunable CD25 upregulation, reduced granzyme B expression, and preserved TCF-1+ stem-like populations depending on signal strength. These results establish mechano-chemically tunable nanocapsule aAPCs as a versatile platform for generating expanded, CD8-enriched T cell products with reduced exhaustion-associated phenotypes for adoptive cell therapy manufacturing and provide a rational framework for programmable T cell product design ex vivo applications.
    Keywords:  T cell activation; aAPCs; antibody density; immunotherapy; mechanotransduction; silica nanocapsules; stiffness
    DOI:  https://doi.org/10.1002/smll.75859
  11. Front Pharmacol. 2026 ;17 1927523
      Biliary tract cancers (BTCs) are aggressive, molecularly heterogeneous malignancies, and most patients present with unresectable or metastatic disease at diagnosis. For more than a decade, gemcitabine-platinum chemotherapy served as the first-line standard of care, with only modest survival benefit. The phase 3 TOPAZ-1 and KEYNOTE-966 trials have now established chemoimmunotherapy with immune checkpoint inhibitors as the new standard front-line regimen, and the phase 2 IMbrave151 trial is evaluating whether adding antiangiogenic therapy provides further benefit. Nonetheless, only a minority of patients derive durable clinical benefit from immunotherapy. Conventional predictive biomarkers-deficient mismatch repair or high microsatellite instability, tumor mutational burden, and PD-L1 expression-have limited discriminatory value in BTC, largely because of profound intratumoral heterogeneity. Emerging biomarkers and composite multi-feature models show greater promise for refining patient stratification. Investigational modalities, including therapeutic cancer vaccines, chimeric antigen receptor T cells, and tumor-infiltrating lymphocyte therapy, have shown preliminary antitumor activity but require validation in larger cohorts. Multiple combination regimens aimed at reversing the immunosuppressive tumor microenvironment are under active investigation, and disease-specific protocols for managing hepatobiliary immune-related adverse events remain an unmet clinical need. In this review, we synthesize the latest evidence on biomarkers, clinical trials, combination strategies, cellular therapies, and safety management for immunotherapy in advanced BTC, and we highlight persistent challenges and future research directions.
    Keywords:  adoptive cell therapy; biliary tract cancers; chemoimmunotherapy; immune checkpoint inhibitors; predictive biomarkers; tumor microenvironment
    DOI:  https://doi.org/10.3389/fphar.2026.1927523
  12. Int J Surg Pathol. 2026 Sep 23. 10668969261472118
      ObjectiveThis study aims to conduct a comprehensive, multidimensional evaluation of how clinical and pathological factors influence invasive disease-free survival (IDFS) and cancer-specific survival (CSS) in patients with human epidermal growth factor receptor 2 (ERBB2/HER2) positive breast cancer receiving adjuvant trastuzumab therapy. Additionally, a stratified assessment will be conducted based on the hormone receptor (HR) status; thereby providing a practical basis for clinical treatment.MethodA total of 643 patients with HER2-positive breast cancer who received adjuvant trastuzumab therapy were retrospectively included. The patients' clinical and pathological information, as well as IDFS and CSS data, were systematically collected and evaluated. Survival analysis was conducted via the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards regression models were used to assess the effects of menstrual status, tumor size, vascular invasion, lymph node involvement, histological grade, histological type, HR status, MKI67 expression, tumor-infiltrating lymphocytes (TILs), HER2 expression, and anthracycline-based chemotherapy on IDFS and CSS. Additionally, clinicopathological characteristics of patients with HER2-positive breast cancer who received trastuzumab treatment were analyzed.ResultAmong all patients, HER2(3+), absence of lymph node metastasis, and anthracycline-based chemotherapy were independently associated with prolonged CSS. Notably, anthracycline use was an independent predictor of longer CSS in HR-negative patients. In the HR-positive subgroup, patients with HER2(3+) status demonstrated a significant CSS benefit compared to those with HER2(2+)/FISH(+) status.ConclusionHER2 expression status affects CSS in patients with HER2-positive breast cancer receiving adjuvant trastuzumab therapy. HR-negative patients may derive clinical benefit from anthracyclines, providing evidence to support anthracycline-based regimens combined with trastuzumab as the adjuvant treatment for HR-negative, HER2-positive breast cancer.
    Keywords:  FISH; HER2; anthracycline drugs; breast cancer; prognosis; trastuzumab
    DOI:  https://doi.org/10.1177/10668969261472118
  13. Cancers (Basel). 2026 Sep 15. pii: 2977. [Epub ahead of print]18(18):
       BACKGROUND/OBJECTIVES: The immune microenvironment of colorectal cancer liver metastases (CRCLM) differs from that of primary colorectal tumors and may influence responses to immunotherapy. We aimed to characterize T cell subsets and checkpoint receptor expression in CRCLM and explore associations with overall survival.
    METHODS: We performed flow cytometric profiling of matched peripheral blood, non-tumor liver tissue, and CRCLM specimens from 17 patients undergoing hepatic metastasectomy. A separate cohort of 19 patients was studied using ex vivo expanded TILs. Kaplan-Meier/log-rank analyses were complemented by Cox models using dichotomized and continuous marker values, median-cut-off and permutation sensitivity analyses, and post hoc clinical covariate comparisons.
    RESULTS: CRCLM showed relative enrichment of CD4+ T cells and depletion of CD8+ T cells. In the fresh cohort, 16 patients (12 deaths) were evaluable for CRCLM TIGIT+ CD4+ cells. The optimized split was associated with shorter survival for the high group (HR 5.26, 95% CI 1.54-17.94; log-rank p = 0.0036). The median-cut-off analysis showed the same direction (HR 3.17, 95% CI 0.92-11.00; p = 0.0551), as did the continuous model (HR 1.69 per 10-percentage-point increase, 95% CI 0.82-3.45; p = 0.153). In the expanded cohort, the optimized high-versus-low HR was 17.47 (95% CI 3.23-94.59; p < 0.001), and the continuous HR was directionally concordant (HR 2.68, 95% CI 0.96-7.51; p = 0.060). Clinical characteristics were balanced between optimized low and high groups.
    CONCLUSIONS: TIGIT+ CD4+ T cell enrichment showed an exploratory association with shorter survival in CRCLM and represents a promising candidate for further prognostic and functional investigation. The separate expanded cohort provided complementary evidence supporting this observation.
    Keywords:  PD-1; T cells; TIGIT; colorectal cancer liver metastases; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3390/cancers18182977
  14. Cancers (Basel). 2026 Sep 18. pii: 3027. [Epub ahead of print]18(18):
       BACKGROUND: Fresh ovarian cancer tissue is a demanding starting material for cellular workflows, particularly when the aim is to obtain tumor-derived suspensions suitable for further TIL-oriented procedures. In this study, we evaluated post-isolation cell concentration and viability in ovarian cancer specimens processed according to a standardized mechanical-enzymatic protocol.
    METHODS: Biological material was collected from 24 patients undergoing routine surgery for ovarian cancer or suspected advanced ovarian malignancy. After macroscopic assessment and exclusion of extensively necrotic tissue, 19 specimens were included in the final analysis. The cohort was dominated by high-grade serous ovarian carcinoma, which accounted for 15 of 19 analyzed cases. Tissue specimens varied markedly in mass, with a median processed tissue weight of 2.05 g and a range from 0.11 to 14.93 g.
    RESULTS: The median final cell concentration was 8.10 × 106 cells/mL, with values ranging from 6.40 × 103 to 9.26 × 108 cells/mL. Median viability was 80.8%, although individual results ranged widely from 2.3% to 98.7%. The calculated median concentration of viable cells was 6.17 × 106 viable cells/mL. Tissue mass showed a moderate positive association with final cell concentration (Spearman's rho = 0.50, p = 0.028), but not with viability.
    CONCLUSIONS: These findings show that standardized processing of ovarian cancer surgical specimens can generate cell suspensions suitable for post-isolation quality assessment, even when the input material is highly variable. The present study focused on early post-isolation quality-control readouts obtained after tumor dissociation and did not evaluate TIL expansion capacity, detailed TIL phenotype, or antitumor function. The wide range of final cell concentrations underlines the biological and practical heterogeneity of ovarian cancer tissue and supports the need for careful reporting of early tissue-processing parameters in TIL-oriented workflows.
    Keywords:  cell viability; gentleMACS; high-grade serous ovarian cancer; ovarian cancer; tissue processing; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.3390/cancers18183027
  15. Front Immunol. 2026 ;17 1927594
      Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of several hematological malignancies, but its broader application remains constrained by the complexity, cost, and time required for conventional ex vivo manufacturing. In vivo CAR T-cell therapy has emerged as a promising next-generation strategy that aims to generate CAR T cells directly within the patient through targeted delivery of CAR-encoding genetic information to endogenous T cells. This approach has the potential to simplify treatment workflows, shorten manufacturing timelines, reduce production costs, and improve the accessibility of CAR-based immunotherapy. In this review, we summarize the conceptual evolution from ex vivo to in vivo CAR T-cell therapy and discuss major delivery platforms for in vivo CAR T-cell generation, including engineered lentiviral vectors (LVs), adeno-associated viral vectors, lipid nanoparticles, polymeric nanoparticles, extracellular vesicles, and fusogenic nanovesicles. We further examine key translational challenges and corresponding optimization strategies, including approaches to improve T-cell targeting specificity and delivery controllability, reduce vector immunogenicity, enhance CAR expression persistence, mitigate safety concerns associated with ectopic transduction or genomic integration, and potentially overcome the physical, antigenic, and immunosuppressive barriers encountered in solid tumors. Finally, we summarize early clinical trial progress and discuss future directions for improving the safety, efficacy, and translational potential of in vivo CAR T-cell therapy. Overall, in vivo CAR T-cell therapy represents an important extension of adoptive cell therapy and may reshape the development and clinical implementation of cell-based immunotherapies.
    Keywords:  clinical translation; gene delivery; in vivo CAR T-cell therapy; lentiviral vectors (LVs); lipid nanoparticles
    DOI:  https://doi.org/10.3389/fimmu.2026.1927594
  16. Proc Natl Acad Sci U S A. 2026 Sep 29. 123(39): e2612774123
      The developmental timing of T cell generation imprints durable functional programs, yet how this shapes antitumor immunity remains unclear. Here, we combine genetic fate mapping with functional assays to dissect how thymic age and peripheral residency regulate CD8+ T cell behavior within the same host. We find that, compared with adulthood-derived CD8+ T cells, the adolescent-derived counterparts consistently exhibit enhanced tumor infiltration, increased effector cytokine production, and superior proliferative fitness. Transcriptomic and phenotypic profiling identify a CXCR3+IL-18Rα+ subset preferentially enriched among adolescent-derived T cells that shares core virtual memory-like features and displays elevated cytotoxic potential. Mechanistically, thymic origin timing and time spent in the periphery independently regulate the abundance and activity of this subset, revealing a two-tier control comprising developmental bias and postthymic remodeling. Functionally, CXCR3+IL-18Rα+ CD8+ T cells mediate potent tumor killing and confer robust therapeutic benefit in adoptive transfer models. Together, these findings establish developmental imprinting as an important determinant of CD8+ T cell heterogeneity and identify CXCR3+IL-18Rα+ CD8+ T cells as key effectors for antitumor immunity.
    Keywords:  CD8+ T cells; antitumor immunity; developmental timing; fate mapping; thymus
    DOI:  https://doi.org/10.1073/pnas.2612774123
  17. Cancer Immunol Res. 2026 Sep 21.
      Cell motility, characterized by random walk and exploratory search movement, enables effector CD8+ T cells to search for sparse antigen-specific cancer targets within a tumor. This is of special relevance for treatment of solid cancers with adoptive T-cell receptor (TCR) T-cell therapy, where administered effector CD8+ T cells recognize specific MHC-I-presented antigens. Cell motility requires cytoskeleton remodeling to facilitate shape changes and movement. Herein, we show that increased mitochondrial Ca2+ levels are essential to reduce cytoskeleton stiffness of effector CD8+ T cells, leading to acquisition of a polarized shape and high motility. IL-21, but not IL-7 or IL-15, was able to raise mitochondrial Ca2+ levels in effector CD8+ T cells and increase their motility without affecting survival and proliferation. This increase in mitochondrial Ca2+ levels triggered by IL-21 was driven by sustaining mitochondrial membrane potential through mitochondrial STAT3, independently of its transcriptional activity. Enhanced motility of effector CD8+ T cells led to a superior killing efficacy of antigen-specific melanoma cells in vitro. Furthermore, enhanced mitochondrial Ca2+-mediated motility of adoptive TCR-specific effector CD8+ T cells resulted in a superior antitumor efficacy of this treatment against solid tumors in vivo. Thus, enhancing effector CD8+ T-cell motility is a promising strategy to boost efficacy of adoptive T-cell therapies against solid tumors.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-26-0401
  18. Medicine (Baltimore). 2026 Sep 25. 105(39): e46834
       BACKGROUND: This bibliometric study aimed to map the global research landscape of immunotherapy for biliary tract cancers (BTC) from 2014 to 2023, identifying key contributors and emerging trends.
    METHODS: We analyzed 481 English-language articles retrieved from the Web of Science Core Collection (2014-2023) using CiteSpace. Parameters included coauthorship, co-citation, keyword co-occurrence, and burst detection.
    RESULTS: Annual publications surged by 80% in 2021 versus 2020. China dominated output (50% of publications), with Fudan University as the top institution. Fan Jia was the most prolific author (7 papers). High-frequency keywords included gemcitabine (first-line chemotherapy), tumor microenvironment, and T cells. Burst keywords indicated emerging foci: tumor-infiltrating lymphocytes and growth factor receptor (e.g., HER2/ERBB2). The most co-cited study (Piha-Paul et al, 2020; 106 citations) reported pembrolizumab efficacy in BTC.
    CONCLUSION: Research accelerated post-2020, driven by clinical trials. China, Fudan University, and Fan Jia are central to BTC immunotherapy research. Future priorities include targeting HER2 and the tumor microenvironment.
    Keywords:  bibliometric analysis; biliary tract cancers; gemcitabine; growth factor receptor; immunotherapy; research trends; tumor microenvironment; tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1097/MD.0000000000046834
  19. Int J Mol Sci. 2026 Sep 19. pii: 8338. [Epub ahead of print]27(18):
      Tumor-infiltrating CD8+ T cells are transcriptionally heterogeneous, and robust features linking their clonal dynamics to experimentally defined tumor reactivity remain incompletely characterized. We integrated single-cell RNA sequencing (scRNA-seq) and paired T-cell receptor sequencing (scTCR-seq) data from 31 single-cell immune datasets to characterize CD8+ T-cell states associated with clonal expansion and tumor reactivity. Across cancers, HLA-II-expressing CD8+ T cells were enriched in activated, cytotoxic, proliferative, exhausted, and terminally differentiated states and were preferentially associated with expanded TCR clonotypes. Pseudotime analysis indicated that HLA-II expression occurs along late differentiation states. HLA-DR blockade reduced CD25 upregulation in activated mixed PBMC and purified CD8+ T-cell cultures and attenuated CellTrace CFSE dilution in purified CD8+ T cells. An HLA-II-associated CD8+ T-cell signature showed cancer-type-dependent survival associations, including longer overall survival in several cohorts. To evaluate its contribution to tumor-reactivity prediction, an expansion-pretrained DNN was adapted using experimentally annotated tumor-reactive and non-tumor-reactive clonotypes from six pancreatic ductal adenocarcinoma samples and evaluated in 2225 functionally annotated CD8+ T cells from three held-out samples. Adding six HLA-II genes improved ROC-AUC across three feature panels from 0.540 to 0.781, 0.626 to 0.732, and 0.838 to 0.878, respectively, and improved PR-AUC from 0.570 to 0.739, 0.640 to 0.718, and 0.799 to 0.869. These findings identify HLA-II expression as a feature of activated and clonally expanded CD8+ T-cell states and support the complementary value of HLA-II-associated transcriptional features for prioritizing candidate tumor-reactive TCRs.
    Keywords:  HLA-II+ CD8+ T cell; TCR-epitope; biomedical engineering; deep learning; single-cell
    DOI:  https://doi.org/10.3390/ijms27188338
  20. Cureus. 2026 Aug;18(8): e114850
      Background Anti-programmed cell death protein-1 (anti-PD-1) immunotherapy has transformed the treatment of advanced melanoma, but durable benefit remains limited to a subset of patients. CD8+ T cell exhaustion contributes to immune escape in the melanoma tumor microenvironment, while the post-transcriptional regulation of exhaustion-associated genes by microRNAs (miRNAs) remains incompletely understood. Objective We characterized miRNA-mRNA regulatory associations in CD8+ T cell exhaustion-enriched melanoma transcriptomes, classified inverse associations as loss-of-repression (LoR) or active suppression (AS), extended the network to candidate long non-coding RNA (lncRNA)-miRNA-mRNA relationships, and examined whether network-derived transcriptomic scores were associated with anti-PD-1 outcomes in independent cohorts. Methods The TCGA-SKCM bulk transcriptomes were filtered by single-sample gene set enrichment analysis (ssGSEA), yielding 121 CD8+ T cell exhaustion-enriched cases and 115 cases with paired miRNA and mRNA measurements. Differentially expressed miRNAs (DEmiRNAs) were identified between fixed high- and low-exhaustion tertiles (n = 38 each) using two-sided Mann-Whitney U tests with Benjamini-Hochberg correction (|log₂FC| ≥ 0.5; false discovery rate (FDR) ≤ 0.05). Database-supported inverse Spearman's correlations (ρ ≤ -0.30; FDR ≤ 0.05) were assembled into a bipartite network. Edges were classified as LoR or AS, and a competing endogenous RNA (ceRNA) extension incorporated DIANA-LncBase/ENCORI lncRNA-miRNA interactions. Nine biologically anchored axes underwent continuous-score analysis and HC3 regression adjusted for tumor purity, CD8, fibroblast/CAF, myeloid, interferon-gamma, and sample type, together with four sensitivity analyses. Exploratory clinical testing used GSE78220 and the pre-PD-1 biopsy subset of the DFCI melanoma cohort (cBioPortal study identifier: mel_dfci_2019). Results Twenty-six DEmiRNAs (20 upregulated and 6 downregulated) formed 326 inverse miRNA-mRNA edges, comprising 263 AS and 63 LoR associations. Six of nine focused axes met the adjusted-support criterion, and all six were AS-classified including upregulated miR-155-5p as the dominant hub, with inverse associations involving FOXO3 (ρ = -0.305, adjusted p = 0.020) and MEIS1, the strongest priority edge (ρ = -0.470, adjusted p < 0.0001). NEAT1, MALAT1, and XIST emerged as the top-degree lncRNA hubs, all classified as AS-sponge type. Exclusion of one solid-tissue-normal specimen left 114 paired tumors, retained 25 DEmiRNAs, and supported seven of nine axes in the tumor-only sensitivity analysis. Relational integration with lncRNA-miRNA records yielded 29,274 candidate chains, including 790 containing a focused miRNA-mRNA edge. Transcriptomic score analyses were negative and exploratory in GSE78220 (mRNA proxy area under the curve (AUC) = 0.631; Mann-Whitney p = 0.269) and in the DFCI melanoma cohort (mRNA topology AUC = 0.453, p = 0.451; lncRNA topology AUC = 0.388, p = 0.0695). Conclusions The LoR/AS framework offers a transparent means of organizing correlative miRNA-mRNA hypotheses in melanoma bulk transcriptomes. The adjusted results favored an AS pattern among the focused axes, but they did not establish CD8+ T-cell-intrinsic regulation, direct miRNA targeting, ceRNA activity, or clinical predictive utility. Experimental testing in sorted or single-cell melanoma CD8+ tumor-infiltrating lymphocyte systems is required.
    Keywords:  anti-pd-1; cerna; immune checkpoint blockade; lncrna; melanoma; microrna; t cell exhaustion; tumor microenvironment
    DOI:  https://doi.org/10.7759/cureus.114850
  21. Breast Cancer. 2026 Sep 21.
       BACKGROUND: Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, characterized by early metastasis, high recurrence rates, and limited targeted therapy options. Pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a well-established prognostic surrogate for long-term outcome, yet reliable predictive biomarkers remain elusive. TREM-1 and TREM-2 are key immune modulators that shape the balance between proinflammatory and immunosuppressive signaling within the tumor microenvironment (TME). This study aimed to evaluate the predictive utility of TREM-1 and TREM-2 expression for pCR in TNBC after NACT.
    METHODS: Pre-treatment biopsies from 71 patients with early or locally advanced TNBC treated with chemotherapy-based NACT were analyzed by immunohistochemistry (IHC) for TREM-1 and TREM-2. Stromal/TIL H-scores were used for the final analysis. Clinical records were reviewed for treatment regimen. Cutoff values were determined using receiver operating characteristic (ROC) analysis based on the Youden index, and multivariable logistic regression was used to identify independent predictors of pCR.
    RESULTS: High stromal TREM-1 expression (> 90) independently predicted higher pCR rates (OR 12.25; p = 0.003), whereas high stromal TREM-2 expression (> 10) correlated with lower pCR likelihood (OR 0.105; p = 0.030). The predefined high Ki-67 group and lower T-stage also predicted pCR. In secondary analyses, tumor-cell TREM-1 and TREM-2 expression were not significantly associated with pCR.
    CONCLUSION: The opposing associations of stromal TREM-1 and TREM-2 with pCR suggest that the TIL-mediated tumor microenvironment may play an important role in shaping treatment sensitivity in TNBC. High TREM-1 expression is linked to an inflammatory, treatment-responsive phenotype, whereas high TREM-2 expression reflects an immunosuppressive, resistant state. Their combined evaluation may provide clinically meaningful insights for predicting therapeutic response and for developing novel immunomodulatory strategies in TNBC.
    Keywords:  Pathologic complete response; TREM-1; TREM-2; Triple-negative breast cancer; Tumor microenvironment; Tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1007/s12282-026-01918-4
  22. Front Immunol. 2026 ;17 1898790
      Interleukin-10 (IL-10) is classically defined as a potent anti-inflammatory cytokine that protects tissues by constraining myeloid activation and limiting inflammatory cytokine production. Yet, accumulating evidence indicates that, in defined contexts, IL-10 can also promote antitumor immunity by enhancing the fitness and cytotoxic programs of CD8+ T cells and natural killer (NK) cells. Conversely, in other tumor contexts, IL-10 may reinforce immunosuppressive myeloid and regulatory programs, and the factors that determine these divergent outcomes remain incompletely understood. Although these effects converge on a common JAK1/TYK2-STAT3 signaling hub, the downstream biological outcomes are combinatorially shaped by the identity, activation, and chromatin state of the responding cell, co-engaged pathways, including STAT1, mTORC1, and NF-κB/AP, receptor abundance, feedback regulation, and the surrounding microenvironment. Recent studies suggest IL-10 can sustain cytotoxic lymphocyte function under tumor microenvironmental stress through effector programming, restraint of terminal exhaustion, mitochondrial metabolic reprogramming, and remodeling of the tumor microenvironment (TME). However, several of these mechanisms remain supported primarily by limited preclinical models and correlative human data. These advances have promoted the development of pharmacokinetically optimized IL-10 variants, tumor-targeted immunocytokines, surrogate bispecific IL-10 receptor agonists, and IL-10-armored adoptive cell therapies. Although several approaches have shown immune activation and preliminary antitumor activity in early-phase studies, pegilodecakin-the only IL-10-based agent to complete a randomized phase III oncology trial-did not improve survival in gemcitabine-refractory pancreatic cancer, underscoring the gap between pharmacodynamic activity and established clinical benefit. In this review, we synthesize mechanistic and translational advances with conflicting and cautionary evidence, discuss safety considerations associated with IL-10-based agents and IL-10-armored cell therapies, and propose a context-dependent framework for their further development based on tumor and microenvironmental features, spatiotemporal control, rational combination strategies, and candidate biomarkers.
    Keywords:  CAR-T cell; CD8+ T cells; IL-10 receptor blockade; T-cell exhaustion; cancer immunotherapy; interleukin-10; metabolic reprogramming; natural killer cells
    DOI:  https://doi.org/10.3389/fimmu.2026.1898790
  23. Cancer Treat Res Commun. 2026 Sep 19. pii: S2468-2942(26)00359-X. [Epub ahead of print]49 101449
      Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive immunity, potentially converting cold tumors into inflamed states. However, clinical translation remains limited by antiviral clearance, heterogeneous delivery, stromal barriers, immunosuppressive cells, and incomplete integration with cellular immunotherapy. This review synthesizes these mechanisms, platforms, and translational challenges. This review emphasizes platform-specific interactions between oncolytic viruses (OVs) and CAR-T, CAR-NK, and tumor-infiltrating lymphocyte (TIL) therapies. OVs may enhance CAR-T trafficking, antigen availability, local immune activation, and resistance to suppressive tumor microenvironmental signals. In CAR-NK therapy, OV-mediated cytokine support and TME remodeling may improve recruitment and activity, although antiviral NK responses can limit viral persistence. TIL therapy is considered separately because it relies on endogenous tumor-antigen recognition rather than engineered CAR targeting. Overall, direct OV-CAR evidence remains largely preclinical and platform-specific, while early clinical experience is more established for OV combinations with TILs and other immunotherapies in human studies. However, these mechanisms are supported predominantly by preclinical and early translational evidence, and direct clinical validation of OV-CAR combinations remains limited. Antiviral clearance, heterogeneous intratumoral infection, neutralizing immunity, delivery constraints, and potentially overlapping inflammatory toxicities may also restrict therapeutic synergy. Finally, we propose biomarker-driven trial designs that incorporate viral pharmacology, TME conversion, antigen-presentation competence, cellular-product persistence, and response assessment in injected and non-injected lesions.
    Keywords:  Adoptive cellular therapy; Car-nk therapy; Car-t therapy; Oncolytic virus; Tumor microenvironment
    DOI:  https://doi.org/10.1016/j.ctarc.2026.101449